Sanofi is investing $431 million (€350 million) in a new vaccine-manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. 

The new facility will allow Sanofi Pasteur, the global vaccines business unit of Sanofi, to meet growing demand of a five-component acellular pertussis (5-acP) antigen. Upon completion in 2021, the new building will also be equipped to produce the antigens used in diphtheria and tetanus vaccines.

Sanofi has 11 sites for the industrial operations of Sanofi Pasteur in vaccines, according to the company’s 2017 annual filing. These sites are located in the following: Argentina (Pilar);  Canada (Toronto); China (Shenzhen); France: Marcy l’Étoile, Val de Reuil, and Neuville; India (Hyderabad); Mexico (Ocoyoacac); Thailand (Chachoengsao); and the US: Swiftwater, Pennsylvania and Pearl River, New York. In 2017, the company produced 470 million containers (syringes and ampuls) filled of vaccines, including outsourced production.

In 2017, the Sanofi Pasteur (Vaccines) Global Business Unit posted net sales of $6.283 billion (€5.101 billion), a 14.5% increase year over year at constant exchanges rates. It represented 14.5% of total 2017 net sales for the company.